TRANQUILITY: Pacibekitug Safely Lowers hs-CRP in ASCVD, With Deepak Bhatt, MD

The interleukin-6 (IL-6) inhibitor pacibekitug (TOUR006) has indicated its safety and efficacy in reducing high-sensitivity C-reactive protein (hs-CRP) levels in patients with 

atherosclerotic cardiovascular disease (ASCVD)

, based on results from the phase 2 TRANQUILITY trial.

American Heart Association’s Scientific Sessions 2025

 in New Orleans, Louisiana, by Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai.

Pacibekitug is an investigational long-acting fully human monoclonal antibody against the IL-6 cytokine, in development by Tourmaline Bio. While the TRANQUILITY trial investigated its efficacy in treating ASCVD, pacibekitug is also under development for thyroid eye disease, with plans to expand into abdominal aortic aneurysm in the future.

“We showed incremental benefit in hs-CRP reduction, and hopefully that will translate into cardiovascular event reduction,” Bhatt said in an exclusive interview with 

. “But this wasn’t a trial designed to measure cardiovascular events. TRANQUILITY was designed to look at safety and to look at hs-CRP, and it seemed to be safe and highly efficacious in reducing risk.”

Patients were included in the TRANQUILITY trial if they were ≥18 years old, had a serum hs-CRP level ≥2.0 mg/L and <15 mg/L, and a diagnosis of CKD. Patients were excluded if they exhibited evidence of active infection, had serious infections within 6 months or >1 episode within 18 months, a known history of immunodeficiency, a history of gastrointestinal ulceration or perforation within 12 months, a history of active diverticulitis, inflammatory bowel disease, or GI abscess within 12 months, among other criteria.

The treatment period lasted 6 months, followed by a follow-up period of an additional 6 months. The primary endpoint was median time-averaged percent change in hs-CRP through day 90, adjusting for baseline. The key secondary endpoint was the percentage of participants achieving time-averaged hs-CRP below 2 mg/L through day 90. Additionally, investigators noted the percentage of participants achieving hs-CRP reductions of ≥50%.

Bhatt and colleagues ultimately included 143 patients, stratifying them by CKD stage and randomly assigning them to receive either pacibekitug 25 mg quarterly, 50 mg quarterly, or 15 mg monthly, or placebo, all delivered subcutaneously. Median age was 71 years, and 62% of patients were women. Baseline estimated glomerular filtration rate and hs-CRP were 43 ml/min/1.73m2 and 4.45 mg/L, respectively.

By day 90, the median time-averaged percent reduction in hs-CRP was 86% for the 50 mg dose, 75% for the 25 mg dose, and 85% for the 15 mg dose, versus 15% for the placebo arm (all 

 <.0001). Several patients achieved hs-CRP reductions ≥50%, and the percentage of patients with hs-CRP <1 mg/L at day 90 was 60%, 45%, and 65% for the 50 mg, 25 mg, and 15 mg arms compared to 13% for placebo (all 

Bhatt and colleagues concluded that hs-CRP was reduced significantly across all prespecified groups with pacibekitug. They also observed significant reductions in serum amyloid A, fibrinogen, and lipoprotein(a). The incidence of adverse events was 54% and 56% in the pooled pacibekitug and placebo arms, respectively. The team noted similar findings for serious adverse events (10% vs 11%), infections (24% vs 22%), and serious infections (4% vs 3%). According to the study abstract, pacibekitug is now the first IL-6 inhibitor to demonstrate sustained and significant reductions in hs-CRP with quarterly dosing.

“Our hope is that, on the basis of the TRANQUILITY trial, there will be a phase 3 trial powered to look at cardiovascular end points,” Bhatt said. “That’s really what the purpose of the TRANQUILITY trial was: to see if it looked like the drug was safe, if it looked like there was an advantage potential over other IL-6 inhibitors, and to proceed with phase 3 testing.”

Pergola P, Szarek M, Zayed H, et al. A Phase 2 Multicenter, Randomized Double-Blind, Placebo-Controlled Study of Monthly or Quarterly Subcutaneous Administration of the Interleukin-6 Inhibitor Pacibekitug in Patients With Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease: 90-Day Analyses from TRANQUILITY. Abstract presented at the American Heart Association’s Scientific Sessions 2025. New Orleans, Louisiana. November 8-10, 2025.

Tourmaline Bio, Inc. A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (TRANQUILITY). ClinicalTrials.gov Identifier: NCT06362759. Updated November 14, 2025. Accessed November 20, 2025. 

https://clinicaltrials.gov/study/NCT06362759

Mishek S. Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease. Tourmaline Bio. May 20, 2025. Accessed November 20, 2025. 

https://ir.tourmalinebio.com/news-releases/news-release-details/tourmaline-bio-announces-positive-topline-results-ongoing-phase

Videos

Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Chronic Kidney Disease

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Naim Alkhouri, MD, is Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.

Using Noninvasive Testing to Guide MASH Treatment Decisions, With Naim Alkhouri, MD

The rapid emergence of pharmacologic options for metabolic dysfunction-associated steatohepatitis (MASH) has introduced a new set of clinical challenges, particularly around identifying which patients are appropriate candidates for treatment.

With both resmetirom and semaglutide now approved by the US Food and Drug Administration for patients with F2-F3 fibrosis, professional societies have emphasized the need for careful noninvasive assessment to avoid treating individuals with cirrhosis until more data become available. However, the practical application of these recommendations is not always straightforward, as liver stiffness thresholds commonly used to exclude patients may inadvertently prevent some individuals with advanced fibrosis from receiving therapies that have the potential to reverse disease progression.

“We know from clinical practice that many patients with liver stiffness above 20, between 20 to 25, may actually have stage 3 fibrosis, not cirrhosis, and if you exclude them automatically, they will miss the opportunity to be treated with the treatment that can reverse fibrosis,” Naim Alkhouri, MD, chief academic officer of Summit Clinical Research and director of the Steatotic Liver Program at North Shore Gastroenterology, explained to 

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025

, Alkhouri presented research examining the performance of noninvasive tests (NITs) in identifying F2/F3 or F4 fibrosis in patients with LSM 15-25 kPa in a large multicenter database of patients with biopsy-proven MASH.

Patients with LSM 15-20 kPa or LSM 20-25 kPa were identified for further analysis. Comparisons were made between those found to have F2/F3 on biopsy versus F4, and NIT performance was compared to biopsy results.

Of 18,402 patients reviewed, 4326 had baseline liver biopsy and LSM results, 882 of whom had LSM between 15-25. Among patients with LSM between 15-20 kPa (n = 586, 66%; n = 354 F2/F3 and n = 232 F4) and 20-25 kPa (n = 296, 34%; n = 141 F2/F3 and n = 155 F4), patients with F4 fibrosis were significantly older (

In patients with LSM 15-20 kPa, investigators noted model performance was highest using Agile 4 (AUC, 0.76; 95% CI, 0.69-0.83), followed by platelet count (AUC, 0.71; 95% CI, 0.66-0.76) and FIB-4 (AUC, 0.69; 95% CI, 0.64-0.75). Among the LSM 20-25 kPa group, platelet count had superior performance (AUC, 0.75; 95% CI, 0.69-0.82), followed by FIB-4 (AUC, 0.73; 95% CI, 0.66-0.80), and Agile 4 (AUC, 0.70; 95% CI, 0.60-0.79).

Combining all tests resulted in an AUC of 0.76 (95% CI, 0.69-0.82) in the 15-20 kPa group and 0.75 (95% CI, 0.66-0.84) in the 20-25 kPa group. To reach ≥90% sensitivity, for the Agile 4 score, a cutoff value of 0.104 was needed in the 15-20 kPa group and 0.099 in the 20-25 kPa group.

“We hope that these recommendations will be useful to providers when they have elevated liver stiffness and they're not sure if they need to proceed with treatment with resmetirom or semaglutide or say no because this patient has cirrhosis,” Alkhouri said.

Editors’ note: Alkhouri reports relevant disclosures with Altimmune, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Rivus, Takeda, and others.

Alkhouri N, Schattenberg J, Patil R, et al. Utility of FIB-4, Agile 4, and Platelet Count to Rule Out Cirrhosis on Biopsy in Patients with LSM Between 15-25 kPa: A Multi-Center Cohort Study. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed November 20, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed November 20, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Alkhouri explains the importance of differentiating F3 from cirrhosis and the utility of different noninvasive tests for identifying these patients.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Delgocitinib cream 20 mg/g treatment produced a “super-response” in a notable subgroup of patients with 

, recent data suggest, characterized by sustained improvements in itch, pain, quality of life, and severity.

These findings on delgocitinib were presented in a poster session at the 

2025 Fall Clinical Dermatology Conference

 in Las Vegas, Nevada. The research was authored by April W. Armstrong, MD, MPH, and a team of other investigators. Delgocitinib cream was previously approved by the US Food and Drug Administration (FDA) for CHE following the DELTA-1 and 2 trials.

Armstrong et al's analysis looked into the durability, magnitude, and consistency of clinical responses to delgocitinib cream 20 mg/g in adult patients living with moderate to severe CHE. They drew on outcomes from the DELTA-1 and DELTA-2 phase 3 studies and their long-term extension, DELTA-3.

Prior DELTA-1 and DELTA-2 study findings demonstrated that delgocitinib therapy led to substantial improvements across a variety of efficacy endpoints. In their current investigation, Armstrong and colleagues set out to characterize the depth of response to delgocitinib treatment following 16 weeks of utilization. They also sought to explore how well patients' responses were maintained in the absence of ongoing therapy during the extension phase of up to 36 weeks.

Across DELTA-1 and DELTA-2, Armstrong and coauthors noted a total of 636 adults had been provided with delgocitinib cream on a twice daily basis for 16 weeks. There were also 319 individuals assigned to a cream vehicle control group. Subjects of these studies completing the initial treatment period were eligible to carry on into the DELTA-3 extension trial, during which they were examined for up to 36 weeks without the use of active therapy.

Armstrong and coauthors' main clinical measures evaluated in this extension included Hand Eczema Symptom Diary (HESD) scores for pain and pruritus, the Hand Eczema Severity Index (HECSI), the Dermatology Life Quality Index (DLQI), and the Investigator’s Global Assessment for CHE (IGA-CHE). By the 16-week point, those treated with delgocitinib cream were shown to have attained markedly better results than subjects assigned to vehicle.

The investigative team found rates of little-to-no itch (HESD itch score 0 or 1) were more than triple among patients on active treatment, observing such responses in 30.0% of delgocitinib-treated subjects versus 9.4% of those in the vehicle-treated arm of the study.

 The team also noted little-to-no pain (HESD pain 0/1) reported by 35.2% of individuals given delgocitinib cream versus 16.0% in the vehicle arm.

In their assessment of quality-of-life impacts, as determined by a DLQI score of 0 or 1, Armstrong and colleagues identified comparable improvements: 33.3% of those in the delgocitinib group attained this threshold, compared with 13.9% of participants in the control group.

 In their assessment of the breadth of response across these 3 domains, 48.0% of delgocitinib recipients attained at least 1 of the “0/1” outcomes, representing minimal pain, minimal pruritus, or no quality of life impact.

This proportion was noted by the investigators as substantially higher than the 23.8% observed among vehicle-treated individuals in the analysis.

 The team additionally found 19.2% of delgocitinib-treated subjects attained all 3 favorable endpoints simultaneously, which Armstrong et al highlighted was more than triple the 5.4% rate observed with vehicle.

In this analysis, consistent clinical improvements were also evident across the treatment period.

 A higher proportion of delgocitinib-treated individuals met the threshold of at least a 4-point in HESD itch (24.1% versus 6.6%) or HESD pain (25.0% versus 9.0%), assessed repeatedly at the 4, 8, 12, and 16-week marks. In a similar conclusion, delgocitinib cream was shown to have yielded increased rates of disease extent and severity improvements, with 27.3% attaining a ≥75% reduction in their HECSI scores versus 8.1% of subjects in the vehicle group.

Durability of response following delgocitinib cessation was looked into over the course of the DELTA-3 extension study.

 The investigators found, among those who attained complete clearance (IGA-CHE 0) at the 16-week mark while on delgocitinib cream, 32.9% maintained full clearance following 8 weeks without using the topical. A meaningful subset, 15.7%, were shown to have continued to exhibit complete clearance 16 weeks post-therapy.

In all, the investigative team's conclusion pointed to a super-response to delgocitinib cream 20 mg/g produced among a notable subgroup of patients, characterized by profound, sustained improvements in various endpoints.

 They also identified a significant proportion of complete responders who preserved their CHE clearance well beyond the active treatment period.

To find out about related information in dermatology, view the latest coverage of the 

Armstrong A, Bernier C, Silverberg J, et al. “Super-response” following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe Chronic Hand Eczema. Poster presented at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S. LEO Pharma. Published July 23, 2025. Accessed July 23, 2025. 

https://www.leo-pharma.com/media-center/news/2025-fda-approval

Articles

Delgocitinib cream 20 mg/g has shown a "super-response" in a subgroup of patients with chronic hand eczema (CHE), leading to sustained improvements in itch, pain, quality of life, and severity. The analysis, based on DELTA-1, DELTA-2, and DELTA-3 trials, demonstrated significant clinical responses over 16 weeks, with some patients maintaining benefits even after treatment cessation. The study highlighted the cream's efficacy in achieving minimal symptoms and quality of life impacts, with a notable proportion of patients achieving complete clearance of CHE symptoms.

These data highlight a super-response following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe CHE.


Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Subgroup with Chronic Hand Eczema See ‘Super Response’ with Delgocitinib Cream

University of Colorado Health Sciences Center

HAE Attacks May Begin as Early as 2 Years Old, With Daniel Soteres, MD, PhD

2025 American College of Allergy, Asthma, & Immunolog (ACAAI) Annual Scientific Meeting

, Daniel Soteres, MD, PhD, from the University of Colorado Health Sciences Center, presented new data on the attack burden affecting children aged 2 – 11 years with 

“The burden of these attacks on children has previously been considered more of [an issue beginning at] the onset of puberty, you know, 11, 12, 14, 15 years old,” Soteres told HCPLive during the meeting. “It turns out when you talk with healthcare providers, the caregivers, and the adolescents who are helping control and manage this disease and understand this disease, that the attacks actually start a lot younger, as early as 5 years old, and some reports even as young as 2.”

The analysis incorporated 3 stakeholder perspectives: caregivers of children aged 2–11 years, adolescents aged 12–17 years who completed the questionnaire themselves, and clinicians across allergy/immunology, pediatrics, and primary care who were interviewed about their experiences treating pediatric HAE. Together, these viewpoints helped characterize daily life disruptions that have not been well quantified in the literature.

Soteres emphasized that HAE attacks in children are often misunderstood. Rather than brief episodes, attacks can escalate over several hours and peak for 2 to 5 days, interfering with school, social activities, sleep, athletics, and family routines.

Participants identified several aspects of attacks that are particularly disruptive: prolonged pain, functional limitations, swelling in visible areas, and embarrassment or fear associated with attacks in sensitive locations such as the mouth or genital region. Soteres noted that clinicians should be aware that these physical and emotional burdens arise earlier than previously recognized, reinforcing the need for timely diagnosis and individualized care planning.

Soteres highlighted the importance of both on-demand and preventive therapy. He noted that all pediatric patients should have rapid access to ≥ 2 doses of on-demand treatment. Preventive strategies, whether daily oral therapies or intermittent injections, can help reduce the frequency and severity of attacks and create greater day-to-day stability for families.

“[We’re still working to understand] uncontrolled hereditary angioedema in the pediatric population,” Soteres said. “The poster we're presenting today gives an important explanation and insight into the disease state in that group.”

Relevant disclosures for Soteres include GENZYME CORPORATION, BioCryst US Sales Co., LLC, Takeda Pharmaceuticals U.S.A., Inc., CSL Behring, Pharming Healthcare, Inc., and AstraZeneca Pharmaceuticals LP.

At ACAAI 2025, HCPLive also spoke with Patricia Stewart, MD, from the Mississippi Asthma & Allergy Clinic, and Raffi Tachdjian, MD, MPH, from UCLA Health, on the burden of HAE attacks among children.

Soteres D. Burden of Attack for Young Patients with Hereditary Angioedema and Their Caregivers. Presented at ACAAI 2025 in Orlando, Florida, from November 6 – 10.

Stewart P. Emergency Care Still Falling Short for Children With HAE, With Patricia Stewart, MD. Hcplive.com. Published November 18, 2025. Accessed November 20, 2025. 

https://www.hcplive.com/view/emergency-care-falling-short-children-hae-patricia-stewart-md

Tachdjian R. Importance of Addressing the Psychosocial Burden of HAE Among Children, With Raffi Tachdjian, MD. Hcplive.com. Published November 18, 2025. Accessed November 20, 2025. 

https://www.hcplive.com/view/importance-addressing-psychosocial-burden-hae-among-children-with-raffi-tachdjian-md

A study presented at ACAAI 2025 reveals HAE attacks may start in toddlers, highlighting significant daily burdens and the importance of timely diagnosis and treatment.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Assistant Professor at the University of Texas Health Science Center at San Antonio

Non-Steroidal Topicals: A Game-Changer for Pediatric Atopic Dermatitis, With Emily Becker, MD

Over the past decade, the atopic dermatitis treatment landscape has undergone a profound transformation. What was once dominated by reliance on topical and systemic steroids has now shifted to precision-targeted therapies, including biologics, JAK inhibitors, and advanced non-steroidal topical agents. Notable recent approvals have helped drive this evolution: for example, nemolizumab (Nemluvio), an IL-31 receptor blocker, was approved by the FDA in December 2024 for patients 12 years and older.

 Meanwhile, tapinarof cream (VTAMA 1%), a once-daily non-steroidal topical aryl hydrocarbon receptor agonist, gained FDA approval for use in children aged 2 and up in December 2024.

 More recently in October 2025, the FDA extended the approval of roflumilast cream 0.05% (Zoryve) for children 2 to 5 years old, offering a long-acting, steroid-free alternative.

 These advances mark a major shift away from steroid dependence and toward more targeted, age-appropriate therapies.

 in Denver, Colorado, dermatologists led by Adelaide Hebert, MD, from University of Texas (UT) Health Houston and Emily Becker, MD, from UT Health San Antonio, gathered to explore how these developments are transforming real-world care for children with atopic dermatitis.

The discussion centered on evolving treatment philosophies, the role of new nonsteroidal topicals in practice, and the ongoing importance of education and advocacy in overcoming barriers to access.

caught up with Becker to discuss some of her takeaways from the recent forum and to learn more about how recent impactful additions to the atopic dermatitis treatment landscape have changed practice for the panelists and life for patients.

Becker reflected on how these changes have reshaped pediatric atopic dermatitis care. She described the “freedom” patients now feel, no longer tied to cycling through various steroids. Instead, providers can offer children and families a full toolbox, from systemic biologics like IL-4/IL-13 or IL-31 inhibitors for severe disease, to non-steroidal topicals for mild-to-moderate cases. According to Becker, this has not only improved efficacy and quality of life, but also restored hope: young pediatric patients now have FDA-approved, safe options starting as early as a few months or years of age, shifting the conversation from off-label use to licensed, accessible treatments.

Becker highlighted several practical and meaningful benefits from this therapeutic evolution. The availability of once-daily non-steroidal topicals has significantly boosted treatment adherence in children and teens: a tube lasts much longer, and the burden of frequent reapplication is greatly reduced. She also noted the profound impact on sleep and itch, which previously had been masked by older therapies like sedating antihistamines which have their own drawbacks. With newer treatments, providers are thinking beyond skin clearance, prioritizing sleep, itch, and overall quality of life when making therapeutic decisions.

"I think in general, the most meaningful change has been this movement away from the dependence on steroids in general," Becker said.

Beyond symptom control, Becker emphasized the move toward proactive, maintenance-based care. While topical steroids remain part of the toolkit, she encourages families to think bigger: envisioning care without topical steroids as part of the regular routine. She also underscored the role of advocacy and shared decision-making: by documenting disease severity, itch burden, and quality-of-life metrics, clinicians and families can strengthen insurance appeals and access discussions. She stressed that all the recent advances in the field have contributed greatly to empowering children and their caregivers to take a more active role in their atopic dermatitis care.

Relevant disclosures for Becker include Organon, Regeneron, Genzyme,
Lilly, Arcutis Biotherapeutics, Incyte Corporation, Dermavant Sciences, LEO Pharma, AbbVie, and Boehringer Ingelheim.

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis. News release. Galderma. December 13, 2024. https://investors.galderma.com/news-releases/news-release-details/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older. News release. Organon. January 3, 2025. https://nationaleczema.org/blog/press-release-vtama-tapinarof-cream-atopic-dermatitis/?utm_source=chatgpt.com

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5. News release. Arcutus. October 6, 2025. https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment?utm_source=chatgpt.com

Johnson V. Proactivity, Not Reactivity: Pediatric Atopic Dermatitis Care in the Modern Era. HCPLive. Article. October 20, 2025. https://www.hcplive.com/view/proactivity-not-reactivity-pediatric-atopic-dermatitis-care-modern-era

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The living guideline incorporates new medications and the latest data to make recommendations for moderate-to-severely active CD care.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

James Ip, MD, is a professor and cardiologist at Weill Cornell Medicine.

Ip highlights the uniform safety of patient-administered etripamil nasal spray across a series of phase 2 and 3 studies.

Self-Administered Nasal Etripamil Restores Sinus Rhythm Safely, With James Ip, MD

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

SCALE-UP: Findings on Real-World Use of Upadacitinib in Atopic Dermatitis

Jonathan A. Bernstein, MD: University of Cincinnati

New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.

Povorcitinib 75 mg Rapidly Reduces Itch and Hives in CSU, With Jonathan Bernstein, MD

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

Clinical Pearls in Pediatric Dermatology Highlighted in 2025 Fall Clinical Conference

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Noureddin explains HU6’s mechanism of action and phase 2 data presented at AASLD The Liver Meeting supporting its use in MASH.

Understanding HU6 and Its Emerging Role in MASH, With Mazen Noureddin, MD, MHSc

Gulati discusses how cardiologists should change their standard care practices to include and educate patients, which will reduce treatment burden and improve adherence.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Broaching the Issue of Patient Education in Heart Failure Care, With Martha Gulati, MD

Jason A. Trubiano, PhD: Melbourne Medical School

At ACAAI 2025, Trubiano discusses repurposed immunomodulators, T-cell–targeted approaches, and genetic screening for delayed hypersensitivity management.

Emerging Strategies for Delayed Hypersensitivity Reactions, With Jason Trubiano, PhD

The panel focuses on recognizing extra-cardiac manifestations that often precede cardiac symptoms in ATTR-CM. Orthopedic signs—such as bilateral carpal tunnel syndrome, cervical or lumbar spinal stenosis, biceps tendon rupture, trigger finger, and recurrent joint replacements—may occur five to ten years before cardiac involvement. Neurologic and autonomic features, including peripheral neuropathy, orthostatic hypotension, constipation, diarrhea, urinary retention, and erectile dysfunction, also serve as early clues, though frequently attributed to aging or unrelated conditions. The discussion emphasizes the importance of educating clinicians across specialties to identify these signals and consider amyloidosis when patterns cluster.
The panel notes that orthopedic surgeons, neurologists, primary care physicians, and geriatricians play key roles in spotting early presentations. Advanced practice providers can also help bridge communication and referral pathways. Rather than screening every patient with common conditions, the group recommends viewing these findings as risk indicators and prompting coordinated evaluation to facilitate earlier diagnosis and treatment.


Video Series

Extra-Cardiac Clues and Care Team Integration for Earlier ATTR-CM Detection

This program brings together leading experts to discuss evolving strategies for reducing recurrent cardiovascular risk in patients with ASCVD, emphasizing the importance of cumulative LDL-C exposure and the need for earlier, more intensive lipid lowering. The panel explores current guidelines, emerging data from recent trials, and practical approaches to integrating PCSK9-targeting therapies to improve long-term adherence, access, and outcomes in secondary prevention

Latest News

TRANQUILITY: Pacibekitug Safely Lowers hs-CRP in ASCVD, With Deepak Bhatt, MD

Using Noninvasive Testing to Guide MASH Treatment Decisions, With Naim Alkhouri, MD

Subgroup with Chronic Hand Eczema See ‘Super Response’ with Delgocitinib Cream

HAE Attacks May Begin as Early as 2 Years Old, With Daniel Soteres, MD, PhD

Non-Steroidal Topicals: A Game-Changer for Pediatric Atopic Dermatitis, With Emily Becker, MD